Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Moderate to Severe Atopic Dermatitis Reaching the Primary Efficacy Endpoint

· Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange

On 6ix: 6ix.com/news/announcement-on-voluntary-disclosure-of-results-of-the-phase-iii-clinical-trial-of-gecacitinib-hydrochloride-tablets-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-reaching-the-primary-efficacy-endpoint

Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Moderate to Severe Atopic Dermatitis Reaching the Primary Efficacy Endpoint

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis